Table 2.

Incidence and OR of irAEs, including 95% CI and number of trials in each analysis

All-grade irAEs	No. of trials	Pooled OR (95% CI)	Pooled OR	P-value	High-grade irAEs	No. of trials	Pooled OR (95% CI)	Pooled OR	P-value
Pruritus	4	(1.739, 2.546)	2.104	P<0.05	Pruritus	4	(2.220, 25.919)	7.585	P<0.05
Rash	4	(1.488, 2.814)	2.046	P<0.05	Rash	4	(2.443, 10.061)	4.957	P<0.05
Vitiligo	2	(0.637, 1.264)	0.897	P<0.05	Vitiligo	2	(0.048, 4.410)	0.458	P<0.05
Diarrhea	4	(1.759, 4.192)	2.715	P<0.05	Diarrhea	4	(2.943, 7.628)	4.738	P<0.05
Colitis	3	(5.833,16.833)	9.909	P<0.05	Colitis	3	(6.148, 26.118)	12.671	P<0.05
ALT elevation	3	(3.732, 7.589)	5.322	P<0.05	ALT elevation	3	(3.819, 12.344)	6.866	P<0.05
AST elevation	3	(3.251, 6.656)	4.652	P<0.05	AST elevation	3	(0.376, 18.554)	2.643	P<0.05
Hypothyroidism	4	(1.413, 2.353)	1.823	P<0.05	Hypothyroidism	4	(0.674, 12.251)	2.874	P<0.05
Hyperthyroidism	3	(1.986, 4.374)	2.947	P<0.05	Hyperthyroidism	2	(1.036, 39.008)	6.356	P<0.05
Hypophysitis	2	(7.360, 46.437)	18.487	P<0.05	Hypophysitis	2	(1.696, 21.973)	6.105	P<0.05
Pneumonitis	3	(2.286, 6.399)	3.825	P<0.05	Pneumonitis	3	(1.206, 16.379)	4.445	P<0.05

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; irAEs, immune-related adverse events; OR, odds ratio.